Topic:
Europe
Latest Headlines
Latest Headlines
Medtronic scores CE mark for novel TAVI valve
Medtronic is rapidly boosting its presence in the heart valve market, winning European approval for Engager, a transcatheter aortic valve implantation system to treat patients with aortic stenosis.
Bayer bucks pharma trend with 'remarkable' growth in new drugs
Bayer's new drugs are bringing home the bacon. The German drugmaker raised its 2015 forecast for 5 key products to €2.5 billion ($3.3 billion)--and confirmed previous promises that those drugs would surpass €5.5 billion by 2020.
U.S., EU on collision course over API rules
Come July 2, all active pharmaceutical ingredients imported into Europe must be certified that they meet EU regulations by the country of their origin.
Officials prepare to dismantle patent rules that stifle drug R&D
As part of an ongoing campaign to streamline the clinical trial process in hopes of spurring its drug R&D industry, U.K. officials are preparing to dismantle patent rules which make it difficult for developers to compare their experimental therapies with currently used standards in clinical studies.
Elan lines up biotech deals as it preps for $3B Tysabri windfall
Dublin-based Elan has told investors how it plans to play the first two rounds in a $3.25 billion game set up by the sale of Tysabri. In a statement this morning the biotech company said it will use the first $1 billion in a share buyback aimed at returning some of the money to investors
Tougher EU device regs? The battle begins in earnest on Feb. 26
An increasingly vocal dustup between device companies and European lawmakers will reach a big milestone on Feb. 26, when both sides will meet during a European Parliament committee meeting and begin trying to hash out a way to strengthen medical device regulations.
Baxter beefing up cytotoxic manufacturing
With the ascent of targeted cancer drugs, a growing number of contract manufacturers are beefing up their cytotoxic manufacturing capabilities to cash in on demand.
Boston Scientific unveils Promus Premier stent in Europe first
Even as stent manufacturers are bumping into each other in Europe vying for business, Boston Scientific ($BSX) is bringing yet another entry into the competition: The Promus Premier.
Swiss stent developer grabs $4.3M series B in crowded EU market
Swiss coronary stent developer Qvanteq is reeling in more than $4.3 million in series B financing, representing the emergence of yet another stent player in an intensely competitive European market.
Smith & Nephew watches profits slip as it reorganizes
European device giant Smith & Nephew posted a 2.3% drop in net profit last quarter, grappling with declining demand for reconstruction tech and plodding through a realignment of its business.
